Hi

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) DI-5782 In Re Application Of: Elisabettini et al. Filing Date Examiner Serial No. Group Art Unit 10/044,234 1616 January 11, 2002 Unknown Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES Address to: **Assistant Commissioner for Patents** Washington, D.C. 20231 37 CFR 1.97(b) Mark The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. DI-5782		
In Re Application: Elisabettini et al.					
Serial No.	Filing Date	Examiner	Group Art Unit		
10/044,234	January 11, 2002	Unknown		1616	
BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES					
Payment of Fee					
(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))					
□ A check in the amount of is attach The Assistant Commissioner is hereby authorized to as described below. A duplicate copy of this sheet is □ Charge the amount of □ Credit any overpayment. □ Charge any additional fee required. Certificate of Transmission by Facsimile* I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F □ (Date) Signature		Certificate of Mailing I certify that this documer 03/29/2002 as first class mail und addressed to the Assistant Washington, D.C. 2023 Signature of Person Robert J. Buccieri	Certificate of Mailing by First Class Mail I certify that this document and fee is being deposited 03/29/2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 2023 Signature of Person Mailing Correspondence		
Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate					
*This certificate may only be used if paying by deposit account. Dated: March 29, 2002 Signature Thomas C. Basso Reg. No. 46,541					
P.O. B x 1135 Chicag , IL 60690-1135					
Phone: (312) 807-4204					
cc:					

1.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Elisabettini et al.

Appl. No.:

10/044,234

Filed:

January 11, 2002

Title:

BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES

Art Unit:

1616

Examiner:

Sir:

Unknown

Docket No.:

DI-5782

Assistant Commissioner for Patents Sashington, DC 20231

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

OTHER DOCUMENTS

- Mehta et al., Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients, Kidney International, Vol. 38 (1990), pp. 976-981.
- van Bommel et al., Continuous Renal Replacement Therapy for Critically Ill Patients: An Update, Journal of Intensive Care Medicine, Vol. 9, No. 6, November-December 1994, pp. 265-280.
- S. Uthoff et al., Improved Correction of Acidosis in Acute Renal Failure Using a Bicarbonate Buffered Substitution Solution, Nephrology (1997), Suppl. 1, P1598.
- A. N. Thomas et al, Comparison of lactate and bicarbonate buffered haemofiltration fluids: use in critically ill patients, Nephrology Dialysis Transplantation, (1997), Vol. 12, pp. 1212-
- Manns et al., Continuous Renal Replacement Therapies: An Update, American Journal of Kidney Diseases, Vol. 32, No. 2 (August) 1998; pp. 185-207.
- Feriani et al., Acid-base balance and replacement solutions in continuous renal replacement therapies, Kidney International, Vol. 53, Suppl. 66 (1998), pp. S-156-S-159.
- Heering et al., The use of different buffers during continuous hemofiltration in critically ill patients with acute renal failure, Intensive Care Medical (1999) Vol. 25, pp. 1244-1251.
- Zimmerman et al., Continuous veno-venous haemodialysis with a novel bicarbonate dialysis solution: prospective cross-over comparison with a lactate buffered solution, Nephrology Dialysis Transplantation, (1999) Vol. 14, pp. 2387-2391.

- Heering et al., Acid-base balance and substitution fluid during continuous hemofiltration, Kidney International, Vol. 56, Suppl. 72 (1999) pp. S-37-S-40.
- Lutkes et al., Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation, Kidney International, Vol. 56 Suppl. 72 (1999) pp. S-71-S-74.
- Kierdorf et al., Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies, Kidney International, Vol. 56, Suppl. 72 (1999) pp. S-32-S-36.
- Barenbrock et al., Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients, Kidney International, Vol. 58 (2000) pp. 1751-1757.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY

Thomas C. Basso Reg. No. 46,541 P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (312) 807-4204